Described as the first antimicrobial dental cavity cleanser cleared by FDA, new product is manufactured by Largent Health, LLC.
Featured on the cover of the October issue of Dental Products Report, FiteBac® Antimicrobial Cavity Cleanser, with 2% K21 is now commercially available in the United States.
Dental cavity cleansers are used for cleansing and moistening/re-wetting of prepared dental surfaces prior to completion of tooth restoration. Largent Health, LLC included in their FDA application, data supporting antimicrobial activity that reduces dentally relevant microbes.1-3
Kirk Kimmerling, DDS, co-inventor of FiteBac technology, says the new product’s technology exemplifies the marriage of antimicrobial technology to material science, enabling the manufacture of modern materials offering sustained, non-leaching antimicrobial protection across a broad range of products. By utilizing a targeted approach to address local microbial issues, dental products incorporating FiteBac technology have the potential to address local microbial issues within the oral cavity while minimizing potential negative impacts on the oral microbiome, a key component to good overall health, Dr Kimmerling says.
The new antimicrobial cavity cleanser contains the patented antimicrobial K21 and is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBac Cavity Cleanser not only helps remove debris in carious lesion preparations, but also helps reduce the presence of dentally relevant organisms within the prepared tooth structure and also penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface.
John W. Sharkey, Ph.D., Chief Executive Officer at Largent Health, says FiteBac is designed to offer dental professionals a differentiated product which, besides helping to ensure the restoration site is clear of carious debris, allows them to directly address residual microbial contamination within the prepared tooth structure.